Methotrexate
One-week methotrexate hold as effective as two-week hold after flu vaccine for RA patients
PHILADELPHIA — Discontinuing methotrexate for 1 week after influenza vaccination offers similar seroprotection as pausing for 2 weeks in patients with rheumatoid arthritis, according to data presented at ACR Convergence 2022.
Severe infection risk for lupus lower with belimumab vs. oral immunosuppressants
PHILADELPHIA — Patients with non-renal systemic lupus erythematosus who receive belimumab demonstrate a lower risk for severe infection vs. those treated with oral immunosuppressants, according to data presented at ACR Convergence 2022.
ACR outgoing president: Rheumatologists must balance ‘activism’ with focus on care
PHILADELPHIA — The “lanes” of medical organizations such as the American College of Rheumatology are widening, as current events require trusted medical professionals to weigh in, said outgoing ACR president Kenneth G. Saag, MD, MSc.
VIDEO: Pegloticase, methotrexate treats uncontrolled gout without compromising kidney
ORLANDO — In this video from ASN Kidney Week, Abdul A. Abdellatif, MD, discusses the efficacy of pegloticase treatment in conjunction with methotrexate for patients with uncontrolled gout.
‘Aggressive therapy’ key in axial spondyloarthritis despite lack of T2T recommendation
SAN DIEGO — Although current American College of Rheumatology guidelines eschew treat-to-target for axial spondyloarthritis, “aggressive treatment” is still needed to manage the disease, noted a speaker here.
‘Negligible’ melanoma risk observed in patients treated with methotrexate
Findings from a comprehensive systematic review and meta-analysis showed a “negligible” risk for melanoma among individuals treated with methotrexate.
Pre-arthritis methotrexate use improves RA course, fails to prevent clinical arthritis
Methotrexate use at the pre-arthritis stage of symptoms and subclinical inflammation fails to prevent clinical arthritis, but does improve symptoms and MRI-detected inflammation vs. placebo, according to data published in The Lancet.
Ozoralizumab reduces RA signs, symptoms in patients who fail methotrexate
Ozoralizumab, in either the 30 mg or 80 mg formulation, significantly reduces rheumatoid arthritis signs and symptoms in patients with an inadequate response to methotrexate, according to data published in Arthritis & Rheumatology.
Olokizumab bests placebo, noninferior to adalimumab in RA with methotrexate
Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in patients with rheumatoid arthritis who were receiving methotrexate as a maintenance therapy, according to data.
Antibody response to COVID-19 booster doubles in patients who paused methotrexate
Patients who suspended methotrexate for 2 weeks after a COVID-19 booster vaccine had a “twofold” increased antibody response, compared with those who remained on the drug, according to data published in The Lancet Respiratory Medicine.